Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum’s Disease

Posted on by

NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ — Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase 2b study for Dercum’s disease (CBL-0202 DD Phase 2b study, NCT06303570) has been initiated. The study results are anticipated in Q4 2025. CBL-0202DD…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.